459Martinez-Forero I, Pelaez A, Villoslada P. Pharmacogenomics of multiple sclerosis: in search for
a personalized therapy. Expert Opin Pharmacother. 2008;9:3053–67.
Menzler K, Hermsen A, Balkenhol K, et al. A common SCN1A splice-site polymorphism modifi es
the effect of carbamazepine on cortical excitability − a pharmacogenetic transcranial magnetic
stimulation study. Epilepsia. 2014;55:362–9.
Németh AH, Kwasniewska AC, Lise S, et al. Next generation sequencing for molecular diagnosis
of neurological disorders using ataxias as a model. Brain. 2013;136:3106–18.
Ning MM, Lopez M, Sarracino D, et al. Pharmaco-proteomics opportunities for individualizing
neurovascular treatment. Neurol Res. 2013;35:448–56.
Oertel B, Lötsch J. Genetic mutations that prevent pain: implications for future pain medication.
Pharmacogenomics. 2008;9:179–94.
Oksenberg JR. Decoding multiple sclerosis: an update on genomics and future directions. Expert
Rev Neurother. 2013;13(12 Suppl):11–9.
Pasinetti GM, Fivecoat H, Ho L. Personalized medicine in traumatic brain injury. Psychiatr Clin
North Am. 2010;33(4):905–13.
Piane M, Lulli P, Farinelli I, et al. Genetics of migraine and pharmacogenomics: some consider-
ations. J Headache Pain. 2007;8:334–9.
Plagnol V, Nalls MA, Bras J, et al. A two-stage meta-analysis identifi es several new loci for
Parkinson’s disease. PLoS Genet. 2011;7(6):e1002142.
Raad M, El Tal T, Gul R, et al. Neuroproteomics approach and neurosystems biology analysis:
ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma.
Electrophoresis. 2012;33:3659–68.
Rafei M, Hsieh J, Zehntner S, et al. A granulocyte-macrophage colony–stimulating factor and
interleukin-15 fusokine induces a regulatory B cell population with immune suppressive prop-
erties. Nat Med. 2009;15:1038–45.
Rakvåg TT, Ross JR, Sato H, et al. Genetic variation in the catechol-O-methyltransferase (COMT)
gene and morphine requirements in cancer patients with pain. Mol Pain. 2008;4:64.
Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer’s risk in APOE varep-
silon4 carriers. Neuron. 2007;54:713–20.
Rice CM, Whone AL, Walsh P, et al. Safety and feasibility of autologous bone marrow cellular
therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther. 2010;87:679–85.
Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically
associated with Alzheimer disease. Nat Genet. 2007;39:168–77.
Rozzini L, Chilovi BV, Bertoletti E, et al. Serum albumin level interferes with the effect of done-
pezil in Alzheimer’s disease. Aging Clin Exp Res. 2008;20:509–12.
Sadhasivam S, Chidambaran V, Olbrecht VA, et al. Genetics of pain perception, COMT and post-
operative pain management in children. Pharmacogenomics. 2014;15:277–84.
Schürks M, Kurth T, Stude P, et al. G protein beta3 polymorphism and triptan response in cluster
headache. Clin Pharmacol Ther. 2007;82:396–401.
Smith AK, Fang H, Whistler T, et al. Convergent genomic studies identify association of GRIK2
and NPAS2 with chronic fatigue syndrome. Neuropsychobiology. 2011;64:183–94.
Stamer UM, Stuber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol.
2007;20:478–84.
Straube A, Aicher B, Fiebich BL, Haag G. Combined analgesics in (headache) pain therapy: shot-
gun approach or precise multi-target therapeutics? BMC Neurol. 2011;1:43.
Subenthiran S, Abdullah NR, Muniandy PK, et al. G2677T polymorphism can predict treatment
outcome of Malaysians with complex partial seizures being treated with carbamazepine. Genet
Mol Res. 2013;12:5937–44.
Sun F, Cavalli V. Neuroproteomics approaches to decipher neuronal regeneration and degenera-
tion. Mol Cell Proteomics. 2010;9:963–75.
Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Exp Opin
Pharmacother. 2007;8:1441–9.
Terrazzino S, Viana M, Floriddia E, et al. The serotonin transporter gene polymorphism STin2
VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J
Pharmacol. 2010;641:82–7.
References